Max Senna Mano

18PUBLICATIONS
99CO-AUTHORS
Cancer therapy (excl. chemotherapy and radiation therapy)Predictive and prognostic markersCancer geneticsMolecular targetsGene expression (incl. microarray and other genome-wide approaches)
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (18)

|Mar 11, 2026
Financial Toxicity in Patients With Breast Cancer Treated at Private Medicine Institutions in Brazil.

Aline Cristini Vieira, Matheus Costa E Silva, Cristiano De Padua Souza

|Mar 06, 2026
Clinical Impact and Clinicopathologic Correlations of Oncotype DX in Hormone Receptor-Positive/HER2-Negative Early Breast Cancer: Real-World Evidence From a Large Brazilian Cohort (GBECAM 0520).

Leandro Jonata de Carvalho Oliveira, Daniella Castro Araújo, Júlio Antonio Pereira de Araújo

|Jan 30, 2026
Cost-Effectiveness of the Oncotype DX Breast Recurrence Score Test in the Brazilian Private Health Care Sector.

Ivan Zimmermann, Carlos Alberto da Silva Magliano, Leandro Jonata de Carvalho Oliveira

|Oct 22, 2025
Budget Impact of the Oncotype DX Test in Early-Stage Breast Cancer for the Brazilian Private Health Care System.

Carlos Alberto da Silva Magliano, Ivan R Zimmermann, Leandro Jonata de Carvalho Oliveira

|Jul 14, 2025
Understanding and overcoming CDK4/6 inhibitor resistance in HR+/HER2- metastatic breast cancer: clinical and molecular perspectives.

Jessé Lopes da Silva, Leandro Jonata de Carvalho Oliveira, Cristiano Augusto Andrade de Resende

|Mar 07, 2025
Germline Genetic Testing in Breast Cancer: Utilization and Disparities in a Middle-Income Country.

Alessandra Borba Anton de Souza, Carlos Barrios, Rafaela Gomes de Jesus

Pageof 3